TY - JOUR
T1 - Adjuvant Systemic Therapies in Breast Cancer
AU - Hernandez-Aya, Leonel F.
AU - Gonzalez-Angulo, Ana M.
PY - 2013/4
Y1 - 2013/4
N2 - Although some women with early breast cancer (BC) may be cured with loco-regional treatment alone, up to 20% of patients with early-stage BC will ultimately experience treatment failure and recurrence. A substantial portion of the success in improving clinical outcomes of patients with BC is related to the standardized use of adjuvant therapies. The identification of tumor subtypes with prognostic value has contributed to the idea of tailoring treatments using biologic predictive factors to identify the patients who will most likely respond to therapy and minimize the exposure of " nonresponders" to the side effects of the treatment.
AB - Although some women with early breast cancer (BC) may be cured with loco-regional treatment alone, up to 20% of patients with early-stage BC will ultimately experience treatment failure and recurrence. A substantial portion of the success in improving clinical outcomes of patients with BC is related to the standardized use of adjuvant therapies. The identification of tumor subtypes with prognostic value has contributed to the idea of tailoring treatments using biologic predictive factors to identify the patients who will most likely respond to therapy and minimize the exposure of " nonresponders" to the side effects of the treatment.
KW - Adjuvant
KW - Adjuvant HER-2-targeted therapy
KW - Adjuvant chemotherapy
KW - Adjuvant endocrine
KW - Breast cancer
UR - http://www.scopus.com/inward/record.url?scp=84875321077&partnerID=8YFLogxK
U2 - 10.1016/j.suc.2012.12.002
DO - 10.1016/j.suc.2012.12.002
M3 - Review article
C2 - 23464697
AN - SCOPUS:84875321077
SN - 0039-6109
VL - 93
SP - 473
EP - 491
JO - Surgical Clinics of North America
JF - Surgical Clinics of North America
IS - 2
ER -